GRTS: gritstonebio.com Cash Calculated per Single Share

Gritstone bio - graphic logo of issuer GRTS

Gritstone bio, Inc. (GRTS) is currently reducing the number of its clinical projects, focusing on a colorectal cancer vaccine amid a funding shortage. Management is restructuring the business under Chapter 11 to preserve key developments. The cash per share confirms this trend, where 0.48 is the current level of the metric. Leading immunologists creating personalized therapies provide high growth potential.

Gritstone bio Inc. (GRTS) - Cash per Share from 07/04/2022 to 11/02/2024

Comprehensive metric breakdowns and analytics for Gritstone Bio (GRTS)

- current quotes and average value forecast:
- market capitalization information:
- cash availability and cash flow indicators:
Comprehensive company analysis:Gritstone Bio (GRTS)
Flagship merchandise of Gritstone bio Inc.

This metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. This metric determines the level of absolute financial stability for each security. For Gritstone bio, Inc. (GRTS), this is a critical resource that ensures the independence of non-cyclical vaccine developments from macroeconomic shocks. An analysis of cash per share allows for an assessment of the capital's margin of safety. The cash per share trend reveals the balance between security and investment efficiency.